Department of Pharmaceutics, Bharat Institute of Technology (BIT), School of Pharmacy, Meerut-250103, UP, India.
Department of Pharmaceutical Chemistry, Prince Sattam bin Abdulaziz University, Al Kharj 11942, Saudi Arabia.
Int J Pharm. 2023 Feb 25;633:122614. doi: 10.1016/j.ijpharm.2023.122614. Epub 2023 Jan 13.
Various neurodegenerative diseases (parkinson, huntington, alzheimer, and amyotrophic lateral sclerosis) are becoming serious global health challenges. Despite various treatment options, successful delivery and effective outcomes have been challenged with several physiological-anatomical barriers, formulation related issues, post-administration hurdles, regulatory constraints, physical hurdles, environmental issues, and safety concern. In the present review, we addressed a brief understanding of pathological and normal condition of blood brain barrier (BBB), rational for brain delivery using nanocarriers, major challenges, advantages of nanomedicine, critical aspects of nanomedicine to translate from bed to clinics, and strategic approaches for improved delivery across BBB. The review addressed various mechanistic perspective for delivery of drug loaded nanocarriers across BBB. Moreover, several reports have been published wherein phytomedicine, exosomes, magnetic nanopartilces, functionalized nanocarriers, cationic nanopartilces, and nano-phytomedicine were investigated for remarkable improvement in neurological disorders. These findings are informative for healthcare professionals, researchers, and scientists working in the domains. The successful application and convincing outcomes of nanomedicines were envisaged with clinical trials conducted on various drugs intended to control neurological disorders (NDs). Conclusively, the review addressed comprehensive findings on various aspects of drug loaded nanocarrier delivery across BBB, considerable risks, potential therapeutic benefits, clinical trial based outcomes, and recent advances followed by future perspectives.
各种神经退行性疾病(帕金森病、亨廷顿病、阿尔茨海默病和肌萎缩侧索硬化症)正成为严重的全球健康挑战。尽管有多种治疗选择,但由于多种生理-解剖屏障、制剂相关问题、给药后障碍、监管限制、物理障碍、环境问题和安全问题,成功的传递和有效的结果受到了挑战。在本综述中,我们简要介绍了血脑屏障(BBB)的病理和正常状态、纳米载体脑内递药的合理性、主要挑战、纳米医学的优势、将纳米医学从实验室转化为临床的关键方面,以及改善跨 BBB 传递的策略方法。该综述讨论了药物负载纳米载体跨 BBB 传递的各种机制观点。此外,已经发表了一些报告,其中研究了植物药、外泌体、磁性纳米颗粒、功能化纳米载体、阳离子纳米颗粒和纳米植物药,以显著改善神经紊乱。这些发现为从事医疗保健的专业人员、研究人员和科学家提供了信息。通过对各种旨在控制神经紊乱(NDs)的药物进行临床试验,预计纳米医学的成功应用和令人信服的结果。综上所述,该综述全面介绍了药物负载纳米载体跨 BBB 传递的各个方面,包括相当大的风险、潜在的治疗益处、基于临床试验的结果以及最新进展和未来展望。